The Max Foundation

Dignity and hope in the face of cancer

themaxfoundation.org

Access to CML Treatment in LMIC

Pat Garcia-Gonzalez, May 2019

ACCESS TO TREATMENT

understanding the universe

HOW DID WE GET HERE

transition from GIPAP to MAS

WHAT HAVE WE ACHIEVED

good, bad and ugly

As advocates our job is to look outside of the circle

The universe of people that need our help is infinite

Access to TKIs, historical perspective

Glivec Approval
2001

Some access to
Tasigna through NOA
2007

Iclusig, Sprycel
Glivec, Tasigna
Max Access Solutions
2017

2001
80 countries
75,000 patients
15 years

2016
Max Access
Solutions Launches
Iclusig, Sprycel

2018
Max Access Solutions
Iclusig, Sprycel, Glivec,
Tasigna, Bosulif

Access map for LMIC, 2019



Number of Patients on CML Treatment as of May 1, 2019

MAX ACCESS SOLUTIONS		PATIENT ACCESS PROGRAMS (MAX)	PATIENT ACCESS PROGRAMS (OTHER)
GLIVEC 13,753		GLIVEC 21,244	GLIVEC 27,000+
TASIGNA 268	SPRYCEL 329	TASIGNA 715	TASIGNA 10,000
BOSULIF 80	ICLUSIG 220		SPRYCEL

Over 73,000+ CML patients supported by access programs in low- and middle-income countries!

MAS active cases on 2nd line treatment



The Good, The Bad and The Ugly

2019 Access to treatment for CML in LMIC

The Ugly

The Ugly in 2019

INDIA

- Delayed transition to MAS due to import taxes
- No commercial Bosulif or Iclusig
- Cumbersome regulatory process for humanitarian access

MALAYSIA

- Waiting list for patients to access first line treatment
- No commercial Sprycel, Bosulif or Iclusig

PHILIPPINES

- Month supply of Glivec over $3,000 USD
- High import taxes
- Patients accessing black market through web

The Bad

The most pervasive barrier to achieving optimal clinical outcomes in CML in LMIC in 2019 is lack of access to PCR

The 5-Year Gap in PCR

TOTAL 5-YEAR GAP

- Fixed costs: $1.9 million
- Variable costs: $27.2 million



Resources needed for monitoring the treatment of our CML patients in the next 5 years is $29 million dollars

Spot On CML

- Developed by Dr. Radich
- Extract RNA from dry blood spot to estimate PCR levels
- Over 15 countries participated, including Mexico and The Philippines.

Solidarity Fund

Provides sustained access to PCR tests for all patients

2018	2019
Bolivia	Rwanda (PIH)
Cambodia	Tajikistan
Haiti	Uganda
Honduras	Nicaragua
Kyrgyzstan	Malawi
Papua New Guinea	
Timor Leste	

The Good

Overall Survival of CML Patients in GIPAP

63,000 GIPAP patients in 93 countries received over 71 million defined daily doses (DDD) of imatinib between 2001 and 2014.



Umeh, et al. submitted 2019

The Good in 2019

THAILAND

GIPAP since 2003 helped 6,000+ patients

2019, patent expiration: government takes over the treatment of all patients

The Good in 2019

VENEZUELA

GIPAP in the early 2000's

Government takes over access to treatment and provides all TKIs

Crisis: 1,500 patients without treatment

2018 Novartis agrees to include in MAS

2018 Glivec available in the country for CML patients

The Good in 2019

KYRGYZSTAN

Located in Central Asia, Capital is Bishkek

Cancer center: The National Center of Oncology

189 patients transitioned from GIPAP to MAS in 2017

432
МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКАЯ ЛАБОРАТОРИЯ
THE MAX FOUNDATION-CEPHEIDE

Ограничения Xpert BCR-ABL Ultra
Хорошая лабораторная практика
Двадцать (20) минут до начала процедуры:

(MAS)
Kyrgyzstan

(MAS)
Max Access Solutions
TheMax Foundation
Kyrgyzstan

Contribute to the Good
Improve the Bad
Change the Ugly

ACKNOWLEDGEMENTS

I would like to acknowledge the following individuals:

- Our Programs team: Local Program Coordinators, Program Officers, Senior Program Managers, Supply Chain managers, Admin team
- Our distribution partners in Tanner Pharma
- Our donor partners: Novartis, BMS, Takeda, Pfizer and Incyte
- Our Implementing partner physicians, patient organizations, Ministries of Health, Cepheid
- Our patients and their families
- Special thanks to Josue Blanco, Senior Brand Manager, for these slides

The Max Foundation

Stay connected with The Max Foundation!

themaxfoundation.org/connect

@stompoutcancer · themaxfoundation · themaxfoundation